A 16 Yin Yang gene expression ratio signature for ER+/node− breast cancer. Issue 6 (15th March 2017)

• Record Type: Journal Article
• Authors: Xu, Wayne; Jia, Gaofeng; Cai, Nianguang; Huang, Shujun; Davie, James R.; Pitz, Marshall; Banerji, Shantanu; Murphy, Leigh
• Is Part Of: International journal of cancer. Volume 140:Issue 6(2017:Mar. 15)
• Page Start: 1413
• Page End: 1424
• Publication Date: 2017-03-15
• Subjects: Yin Yang -- Gene Expression -- Signature -- Breast cancer; Cancer -- Periodicals; Cancer -- Prevention -- Periodicals; 616.994
• DOI: 10.1002/ijc.30556
• Languages: English
• ISSNs: 0020-7136

Abstract

Abstract : Breast cancer is one of the leading causes of cancer death in women. It is a complex and heterogeneous disease with different clinical outcomes. Stratifying patients into subgroups with different outcomes could help guide clinical decision making. In this study, we used two opposing groups of genes, Yin and Yang, to develop a prognostic expression ratio signature. Using the METABRIC cohort we identified a16‐gene signature capable of stratifying breast cancer patients into four risk levels with intention that low‐risk patients would not undergo adjuvant systemic therapy, intermediate‐low‐risk patients will be treated with hormonal therapy only, and intermediate‐high‐ and high‐risk groups will be treated by chemotherapy in addition to the hormonal therapy. The 16‐gene signature for four risk level stratifications of breast cancer patients has been validated using 14 independent datasets. Notably, the low‐risk group ( n = 51) of 205 estrogen receptor‐positive and node negative (ER+/node−) patients from three different datasets who had not had any systemic adjuvant therapy had 100% 15‐year disease‐specific survival rate. The Concordance Index of YMR for ER+/node negative patients is close to the commercially available signatures. However, YMR showed more significance (HR = 3.7, p = 8.7e‐12) in stratifying ER+/node− subgroup than OncotypeDx (HR = 2.7, p = 1.3e‐7), MammaPrint (HR = 2.5, p = 5.8e‐7), rorS (HR = 2.4, p = 1.4e‐6), and NPI (HR = 2.6, p = 1.2e‐6). YMR signature may be developed as a clinical tool to select a subgroup of low‐risk ER+/node− patients who do not require any adjuvant hormonal therapy (AHT). Abstract : What's new? Various multigene signatures serve as biomarkers for breast cancer. Many, however, were developed from training datasets and exhibit inconsistencies in reproducibility and reliability. In the present study, an alternative approach, a Yin and Yang gene expression mean ratio (YMR), based on the opposing effects of two gene groups, was used to determine the need for adjuvant systemic therapy in low‐risk breast cancer patients. Free from the constraints of training data, YMR out‐performed other signatures in the stratification of low‐risk estrogen receptor‐positive/node‐negative patients. Used clinically, YMR could potentially allow low‐risk patients to safely opt out of systemic adjuvant therapy.